Marinus Pharmaceuticals Inc

NASDAQ:MRNS  
9.30
-1.02 (-9.88%)
Earnings Announcements

Marinus Pharma Reports Third Quarter 2021 Financial Results

Published: 11/09/2021 12:20 GMT
Marinus Pharmaceuticals Inc (MRNS) - Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results.
at September 30, 2021, Co Had Cash, Cash Equivalents, and Investments of $145.1 Million.
For FY 2021, Co Expects Barda Revenues in Range of $6 to $8 Million.
Qtrly Net Loss per Share $0.53.
Qtrly Total Revenue $10.1 Million Versus $171,000.
Q3 Earnings per Share View $-0.73, Revenue View $2.2 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $3.47 Million
Adjusted EPS is expected to be -$0.77

Next Quarter Revenue Guidance is expected to be $4.3 Million
Next Quarter EPS Guidance is expected to be -$0.77

More details on our Analysts Page.